

In re Application of: Evans et al.
Application No.: 09/522,753
Filing Date: March 10, 2000
Page 11 of 38

PATENT
Attorney Docket No.: SALK1510-3
(088802-8704)

Please replace the originally submitted Figures 4, 5, 6, 9 and 12 with the enclosed replacement Figures (5 sheets of drawings enclosed).

In the claims:

Please replace original claims 1, 3, 5, 6, 9, 10, 12, 14, 15 and 23 with amended forms thereof as follows:

A21
1. (Amended) An isolated polynucleotide encoding a member of a family of silencing mediators of retinoic acid receptor and thyroid hormone receptor (SMRT), or an isoform or peptide portion thereof (collectively, a SMRT co-repressor), or an isolated polynucleotide complementary thereto, wherein said SMRT co-repressor is capable of mediating the transcriptional silencing of at least one member of the steroid/thyroid hormone superfamily of receptors.

C
A22
3. (Amended) The polynucleotide of claim 1 and polynucleotides that hybridize thereto under stringent conditions, wherein the SMRT co-repressor comprises a repression domain having

- a) less than about 83% identity with a Sin3A interaction domain of N-CoR set forth as amino acids 255 to 312 of SEQ ID NO: 11;
- b) less than about 57% identity with repression domain 1 of N-CoR set forth as amino acids 1 to 312 of SEQ ID NO: 11;
- c) less than about 66% identity with a SANT domain of N-CoR set forth as amino acids 312 to 668 of SEQ ID NO: 11; or
- d) less than about 30% identity with repression domain 2 of N-CoR set forth as amino acids 736 to 1031 of SEQ ID NO: 11.

In re Application of: Evans et al.

Application No.: 09/522,753

Filing Date: March 10, 2000

Page 12 of 38

PATENT

Attorney Docket No.: SALK1510-3

(088802-8704)

A23
C1

5. (Amended) A polynucleotide according to claim 1, which hybridizes under stringent conditions with SEQ ID NO:5.

6. (Amended) A polynucleotide according to claim 1, which has at least 80% sequence identity with SEQ ID NO:5.

A24
C2

9. (Amended) The polynucleotide of claim 8, wherein said polynucleotide encodes a polypeptide having substantially the same amino acid sequence as set forth in SEQ ID NO: 7 or conservative variations thereof.

10. (Amended) The polynucleotide of claim 8, which has a nucleotide sequence substantially the same as set forth in SEQ ID NO: 6.

A25
C3

12. (Amended) The polynucleotide of claim 11, wherein said polynucleotide encodes a polypeptide having substantially the same amino acid sequence as set forth in SEQ ID NO: 9 or conservative variations thereof.

Sub C3

14. (Amended) The polynucleotide of claim 1, comprising a nucleotide sequence selected from the group consisting of:

- A26
- (a) nucleotides 1 to 3094 of SEQ ID NO: 4;
 - (b) nucleotides 1 to 3718 of SEQ ID NO: 6;
 - (c) nucleotides 1 to 2801 of SEQ ID NO: 8 and
 - (d) polynucleotides hybridizing under stringent conditions to (a), (b), or (c).

15. (Amended) A polynucleotide that hybridizes under stringent conditions with a polynucleotide according to claim 14, provided that the polynucleotide does not contain a sequence identical to SEQ ID NO: 11.

In re Application of: Evans et al.

PATENT

Application No.: 09/522,753

Attorney Docket No.: SALK1510-3

Filing Date: March 10, 2000

(088802-8704)

Page 13 of 38

23. (Amended) An isolated oligonucleotide, comprising at least 15 nucleotides that can hybridize specifically to the polynucleotide of claim 1, but neither to a polynucleotide encoding SEQ ID NO: 11 nor to a polynucleotide encoding an amino acid sequence consisting of amino acids 1031 to 2517 of SEQ ID NO: 5.

✓
Please cancel claim 2 without prejudice.